News

UroToday22h
ASCO 2025: IL-15RαFc Superagonist SHR-1501 with or Without Bacille Calmette Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: A Phase 1/2 Study
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.
UroToday22h
ASCO 2025: Prognostic Relevance of Aurora Kinase a Expression in Prostate Cancer
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Maroun Bou Zerdan discussing the prognostic relevance of Aurora kinase A expression in prostate ...
UroToday22h
ASCO 2025: Neoadjuvant Lenvatinib plus Pembrolizumab for Resectable Clear-Cell Renal Cell Carcinoma (PELUR): A Prospective Phase 2 Study
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.
UroToday22h
ASCO 2025: Molecular and Clinical Characterization of KLK2 mRNA Expression in Prostate Cancer
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Rana McKay discussing the molecular and clinical characterization of KLK2 mRNA expression in ...
UroToday22h
AUA 2025: Should Primary, Solitary, and Small (3 cm) TaHG Tumors Be Classified as Intermediate- or High-Risk Disease? A Retrospective, International Cohort Study
(UroToday.com) At the 2025 AUA Annual Meeting in Las Vegas, Dr. Jethro C.C. Kwong, from the University of Toronto, presented a retrospective international cohort study addressing a pressing ...